Steven C. Campbell, MD, PhD, is a Professor of Surgery and a member of the Section of Urologic Oncology in the Glickman Urological Institute at The Cleveland Clinic. He obtained his MD and PhD degrees at The University of Chicago and then completed a Urology Residency at The Cleveland Clinic (1989–1995), followed by a fellowship in Urologic Oncology at Memorial Sloan-Kettering Cancer Center (1995–1996). Dr. Campbell’s primary interests include renal cell carcinoma, bladder cancer, prostate cancer, and tumor angiogenesis. His background also includes American Foundation for Urological Diseases (now known as the American Urological Association Foundation) and Kimmel Research Scholarship Awards. He is chair of the Society of Urologic Oncology Exam Committee and a member of the American Board of Urology Examination Committee. Dr. Campbell has edited or co-edited three textbooks about kidney cancer and authored or co-authored the chapter on kidney cancer in Campbell/Walsh Urology, the premier textbook in Urology, for the past four editions.Brian I. Rini, MD, FACP is a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University in Cleveland, Ohio. A staff member of the Department of Solid Tumor Oncology and co-leader of the Genitourinary Program of the CASE Comprehensive Cancer Center, Dr. Rini’s work focuses on genitourinary malignancies. Dr. Rini earned his medical degree at the Ohio State University College of Medicine. Dr. Rini completed a Residency program in Internal Medicine and a Fellowship in Hematology/Oncology at University of Chicago Hospitals. Dr. Rini was an Assistant Professor at the University of California San Francisco before moving to The Cleveland Clinic. Dr. Rini’s primary research has been in renal cell carcinoma (RCC) and prostate cancer, with special focus on antiangiogenic therapy and immunotherapy. Dr. Rini has been involved in the initial and ongoing development of targeted agents for metastatic RCC, and was an integral investigator in the clinical development of several agents which are now FDA approved. Dr. Rini was the Principal Investigator of an international phase III cooperative group trial of bevacizumab plus interferon and the PI of the phase III axitinib trial in metastatic RCC that lead to FDA approval, and is currently the PI of several global phase III trials in RCC. Dr. Rini’s research has been published in peer-reviewed journals including, Journal of the National Cancer Institute, Journal of Clinical Oncology, Cancer, Lancet and JAMA. He is a member of the editorial boards of Journal of Clinical Oncology and co-chair of the NCI RCC Task Force.Robert G. Uzzo, MD, FACS, is currently the G. Willing "Wing" Pepper Chair in Cancer Research. He is a professor and chairman at the Department of Surgery at Fox Chase Cancer Center and Temple University School of Medicine. Dr. Uzzo graduated Summa Cum Laude from Union College prior to attending Cornell University Medical College. He completed two years of general surgical training at The New York Hospital-Cornell Medical Center and Memorial Sloan-Kettering Cancer Center under the tutelage of G. Thomas Shires, MD. Dr. Uzzo went on to complete four years of urologic surgical training at The New York Hospital-Cornell Medical Center and Memorial Sloan-Kettering Cancer Center under the guidance of E. Darracott Vaughan, MD. He then became an American Foundation for Urological Diseases (now the American Urological Association Foundation) Scholar in Urological Oncology at the Cleveland Clinic under the direction of Andrew C. Novick, MD. Dr. Uzzo completed a second fellowship in Renal Vascular Surgery and Transplantation at the Cleveland Clinic Foundation. He has an active and funded lab researching the basic mechanisms of kidney and prostate cancer. His clinical interests are in minimally invasive urological oncology. He is the national urology principal investigator for the E.C.O.G. 2805 (A.S.S.U.R.E.) trial and is the co-chair of the genitourinary early management committee at E.C.O.G. Dr. Uzzo is a member of the American Urologic Association, a fellow in the American College of Surgeons, a member of the American Association of Cancer Research, the Society for Basic Urological Research, the Society of Urological Oncology, and also on the medical advisory board for the Kidney Cancer Association. He has authored more than 300 peer reviewed articles and chapters in urology and urologic oncology and has been the recipient of numerous awards.Brian R. Lane, MD, PhD, FACS, is currently Chief of Urology at Spectrum Health Medical Group. He obtained his MD and PhD degrees in Cellular and Molecular Biology at the University of Michigan Medical School and then completed a Urology Residency and Fellowship in Urologic Oncology at The Cleveland Clinic. Dr. Lane was named an American Urologic Association Foundation Scholar and is a former member of the American Council for Graduate Medical Education Review Committee for Urology. He is currently the Director of Robotic Surgery in the Department of Surgical Subspecialties as well as the Physician Lead in the Robotic and Advanced Minimally Invasive Surgery Program at Spectrum Health. Dr. Lane is also an Associate Professor in the Department of Surgery at Michigan State University. His primary clinical interests include kidney cancer, prostate cancer, bladder cancer, testicular cancer, and adrenal cancer. Dr. Lane’s research has focused on characterizing molecular factors involved in angiogenesis and kidney cancer and predicting outcomes in kidney cancer patients. He has authored more than 100 peer-reviewed publications in urology and oncology. '
